Small-Scale Assays for Studying Dissolution of Pharmaceutical Cocrystals for Oral Administration

The purpose of this study was to better understand the dissolution properties and precipitation behavior of pharmaceutical cocrystals of poorly soluble drugs for the potential for oral administration based on a small-scale dissolution assay. Carbamazepine and indomethacin cocrystals with saccharin and nicotinamide as coformers were prepared with the sonic slurry method. Dissolution of the poorly soluble drugs indomethacin and carbamazepine and their cocrystals was studied with a small-scale dissolution assay installed on a SiriusT3 instrument. Two methodologies were used: (i) surface dissolution of pressed tablet (3 mm) in 20 mL running for fixed times at four pH stages (pH 1.8, pH 3.9, pH 5.4, pH 7.3) and (ii) powder dissolution (2.6 mg) in 2 mL at a constant pH (pH 2). Improved dissolution and useful insights into precipitation kinetics of poorly soluble compounds from the cocrystal form can be revealed by the small-scale dissolution assay. A clear difference in dissolution/precipitation behaviour can be observed based on the characteristics of the coformer used.

[1]  Jukka Rantanen,et al.  Simultaneous UV imaging and raman spectroscopy for the measurement of solvent-mediated phase transformations during dissolution testing. , 2014, Journal of pharmaceutical sciences.

[2]  J. W. Moore,et al.  Mathematical comparison of dissolution profiles , 1996 .

[3]  R. Bogner,et al.  Solution-mediated phase transformation: significance during dissolution and implications for bioavailability. , 2012, Journal of pharmaceutical sciences.

[4]  C. Strachan,et al.  Characterizing the conversion kinetics of carbamazepine polymorphs to the dihydrate in aqueous suspension using Raman spectroscopy. , 2006, Journal of pharmaceutical and biomedical analysis.

[5]  Orn Almarsson,et al.  Performance comparison of a co-crystal of carbamazepine with marketed product. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[6]  Narayan Variankaval,et al.  Preparation and Solid-State Characterization of Nonstoichiometric Cocrystals of a Phosphodiesterase-IV Inhibitor and l-Tartaric Acid , 2006 .

[7]  Jeanette T. Dunlap,et al.  Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids. , 2004, Journal of the American Chemical Society.

[8]  David R. Weyna,et al.  Impact of pharmaceutical cocrystals: the effects on drug pharmacokinetics , 2014, Expert opinion on drug metabolism & toxicology.

[9]  S. Kumar Pharmaceutical Cocrystals: An Overview , 2017 .

[10]  Orn Almarsson,et al.  Crystal engineering of novel cocrystals of a triazole drug with 1,4-dicarboxylic acids. , 2003, Journal of the American Chemical Society.

[11]  Kristyn Greco,et al.  Solution-mediated phase transformation of salts during dissolution: investigation using haloperidol as a model drug. , 2011, Journal of pharmaceutical sciences.

[12]  N. Fotaki,et al.  Pharmaceutical characterisation and evaluation of cocrystals: Importance of in vitro dissolution conditions and type of coformer. , 2013, International journal of pharmaceutics.

[13]  Aeri Park,et al.  Use of a Glutaric Acid Cocrystal to Improve Oral Bioavailability of a Low Solubility API , 2006, Pharmaceutical Research.

[14]  P York,et al.  Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. , 2007, Advanced drug delivery reviews.

[15]  Hywel D Williams,et al.  Strategies to Address Low Drug Solubility in Discovery and Development , 2013, Pharmacological Reviews.

[16]  T. Rades,et al.  The Influence of Pressure on the Intrinsic Dissolution Rate of Amorphous Indomethacin , 2014, Pharmaceutics.

[17]  N. Rodríguez-Hornedo,et al.  Pharmaceutical cocrystals and poorly soluble drugs. , 2013, International journal of pharmaceutics.

[18]  John Comer,et al.  The " dissolution" method: a low volume, in vitro apparatus for assessing the dissolution/precipitation behaviour of an active pharmaceutical ingredient under biorelevant conditions. , 2011, Analytical methods : advancing methods and applications.

[19]  Yoshiki Hayashi,et al.  Dissolution Improvement and the Mechanism of the Improvement from Cocrystallization of Poorly Water-soluble Compounds , 2008, Pharmaceutical Research.

[20]  Mark McAllister,et al.  Early pharmaceutical profiling to predict oral drug absorption: current status and unmet needs. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[21]  A. Newman,et al.  Pharmaceutical Cocrystals and Their Physicochemical Properties , 2009, Crystal growth & design.

[22]  J. Dearden,et al.  The intrinsic aqueous solubility of indomethacin , 2014 .

[23]  R. Holm,et al.  Use of pharmaceutical salts and cocrystals to address the issue of poor solubility. , 2013, International journal of pharmaceutics.

[24]  Sekhar Surapaneni,et al.  The co-crystal approach to improve the exposure of a water-insoluble compound: AMG 517 sorbic acid co-crystal characterization and pharmacokinetics. , 2008, Journal of pharmaceutical sciences.

[25]  Niklas Sandler,et al.  Pharmaceutical co-crystals-an opportunity for drug product enhancement. , 2009, Expert opinion on drug delivery.

[26]  Ashwini Nangia,et al.  Nitrofurantoin-p-aminobenzoic acid cocrystal: hydration stability and dissolution rate studies. , 2011, Journal of pharmaceutical sciences.